Every material Form 8-K Veradermics, Inc has filed with the SEC since July 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Veradermics reported positive topline 12-month results from Part B of Study '302', a Phase 2/3 trial of its lead candidate VDPHL01 in 519 men with mild-to-moderate pattern hair loss, and reported no new safety signals. The filing covers clinical trial data only and includes no revenue, earnings, or guidance figures, and the drug has not been approved for sale.
Non-vellus hair count rose 43.9 hairs/cm2 (twice daily) and 29.7 hairs/cm2 (once daily) from baseline to Month 12 in the continued group.
At Month 12, 89.1% (twice daily) and 79.8% (once daily) of continued-group participants reported visible improvement in hair coverage on the AAIRS scale.
No treatment-related serious adverse events and no adverse event-related study discontinuations were reported between Month 6 and Month 12.
The company plans to announce data from Study '306' in women in the first half of 2027.
Veradermics said its Phase 3 Study '304' of VDPHL01, an oral extended-release minoxidil tablet, met all primary and secondary endpoints with high statistical significance in 536 men with mild-to-moderate pattern hair loss. The company reported no treatment-related serious adverse events and no cardiac adverse events of special interest, and it said the results add to positive data from Study '302' for a potential first FDA-approved oral non-hormonal treatment for men, though approval has not been sought or granted.
At Month 6, hair count rose 28.6 hairs/cm² (once daily) and 36.4 hairs/cm² (twice daily) versus 6.6 hairs/cm² for placebo, each with p<0.0001.
55.7% (once daily) and 68.7% (twice daily) of patients reported 'improved' or 'much improved' hair coverage versus 15.0% on placebo.
Hypertrichosis was the only adverse event above 5% with a difference from placebo: 2.2% (once daily) and 9.0% (twice daily) versus 0% on placebo.
Veradermics plans to report Part B of Study '302' later in 2026.
Veradermics reported a second-quarter 2026 net loss of $23.5 million, up from $15.6 million a year earlier, as research and development and general and administrative costs rose. The company had $819.9 million in cash, cash equivalents and marketable securities on June 30, 2026, after raising about $472.0 million in gross proceeds in May 2026, and it expects that cash to fund operations into 2030.
Net loss was $23.5 million for Q2 2026 versus $15.6 million for Q2 2025.
R&D expenses rose to $18.6 million from $14.3 million; G&A expenses rose to $10.9 million from $1.7 million.
Cash, cash equivalents and marketable securities were $819.9 million on June 30, 2026, up from $141.9 million on December 31, 2025.
Topline data from Phase 2/3 Study '306' are expected in the first half of 2027; Study '304' and 12-month Study '302' data are expected in the second half of 2026.
Veradermics said topline results from its open-label Phase 2 Study 207 showed increases in hair count and patient-reported improvement in women with mild-to-moderate pattern hair loss after six months of oral VDPHL01 treatment. The company said the results support its registration-directed Phase 2/3 Study 306 in women, with topline data expected in the first half of 2027. The filing contains no financial results, and the study was open-label.
Study 207 enrolled 28 adult female participants; women on VDPHL01 4.5 mg once daily or twice daily showed mean non-vellus hair count increases of 22.7 and 23.3 hairs/cm² at Month 6.
88.9% (once daily) and 90.0% (twice daily) of women rated improved or much improved on the AAIRS at Month 6.
No treatment-related serious adverse events were reported; the most common adverse events were hypertrichosis and peripheral edema.
Topline results from Phase 2/3 Study 306 in women are anticipated in the first half of 2027.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Veradermics, Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →